GlassScriptPhysician profile
Marta Klisinska
NPI 1720491251
$8,598.22
in general payments reported to CMS, 2019-2025
42 companies · $978 in 2025
The $978 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $1,063 · 2021: $1,208 · 2022: $788 · 2023: $1,688 · 2024: $1,360 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,025.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,633.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,192.57 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $708.56 | 2020-2024 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $661.12 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Medtronic, INC. | $532.88 | 2021-2025 | Inceptiv, Closurefast |
| Lilly USA, LLC | $475.93 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $377.55 | 2019-2021 | |
| Amgen INC. | $366.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $344.70 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $299.84 | 2019-2023 | |
| Abbott Laboratories | $219.52 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Atricure, INC. | $156.89 | 2022 | |
| Cequr Corporation | $142.79 | 2025 | Cequr Simplicity |
| Abbvie INC. | $136.53 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $115.53 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Amarin Pharma, INC. | $113.53 | 2019 | |
| Merck Sharp & Dohme LLC | $112.83 | 2020-2025 | Capvaxive, Gardasil 9 |
| Stryker Corporation | $103.03 | 2019 | |
| Astellas Pharma US INC | $91.04 | 2023-2025 | Veozah, Myrbetriq |
| Intuitive Surgical, INC. | $85.89 | 2023 | Da Vinci Surgical System |
| Exact Sciences Corporation | $85.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $63.06 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $44.45 | 2021 | |
| Daiichi Sankyo INC. | $43.66 | 2019-2021 | |
| Medtronic Vascular, INC. | $43.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.05 | 2020-2021 | |
| Becton, Dickinson and Company | $35.56 | 2025 | Bd Veritor Plus Analyzer |
| Eisai INC. | $33.96 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.78 | 2022 | |
| Seqirus USA INC | $20.97 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.05 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $18.68 | 2021 | |
| Hologic Sales and Service, LLC | $17.77 | 2021 | |
| Philips North America LLC | $16.29 | 2024 | (Ck7) Extended Holter |
| Gilead Sciences, INC. | $15.97 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2019 | |
| Ibsa Pharma INC. | $15.00 | 2021 | |
| Ethicon US, LLC | $13.98 | 2020 | |
| Mannkind Corporation | $13.21 | 2020 | |
| Exeltis, USA INC. | $11.48 | 2021 | |
| Cvrx, INC. | $6.34 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Klisinska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.